Friday, July 31, 2026

Porsche’s Icon Goes Hybrid: New 911 Carrera 4 GTS to Debut in Seoul

Porsche Korea will unveil the new 911 model at the 2025 Seoul Mobility Show, marking its first domestic reveal.

Dollar-Won Exchange Rate Could Top 1,450 with Trump’s Tariffs Causing Market Jitters

Woori Bank predicts the dollar-won rate may exceed 1,450 won due to tariff pressures and market reactions to trade disputes.

FIFA World Cup 2026: Can Argentina Defend Their Title Against Switzerland?

The quarterfinals of the 2026 FIFA World Cup feature six European teams, Argentina, and Morocco, with thrilling matchups ahead.

Tag: diabetes

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Unlocking Health: Yuhan Corporation Launches Glucobiotic Probiotic for Diabetes Management in Mexico

Yuhan Corporation launches Glucobiotic in Mexico, targeting diabetes with a probiotic backed by extensive research and local partnerships.

Eli Lilly’s Retatrutide: The Revolutionary Triple Hormone Treatment for Obesity – What You Need to Know

Eli Lilly's retatrutide shows promising results in Phase 3 trials, aiming for FDA approval for obesity and related conditions in 2027.

‘Dream Weight-Loss Drug’ Wegovy May Also Protect Brain Health by Reducing Risk of Adult-Onset Seizures

Semaglutide may reduce adult-onset seizure risk by 56%, suggesting a link between metabolic treatment and brain health.

How Salidroside from Korean Ginseng Can Combat Insulin Resistance and Prevent Diabetes

Research reveals salicin from tianma improves insulin resistance, aiding diabetes prevention and intestinal health restoration.

Metabolic Surgery for Obese Seniors: A Safe Solution for Diabetes and Hypertension?

A study shows metabolic obesity surgery is safe for patients over 55, improving diabetes and other metabolic diseases effectively.

Daewoong Pharma Signs $1.45 Billion MENA Export Deal for ‘Enavogliflozin,’ Marking Record Global Sales

Daewoong Pharmaceutical's diabetes drug Enblo secures a $1.45 billion deal to enter MENA markets, marking a significant milestone.

Continuous glucose monitors linked to 62% lower risk of death in Type 1 diabetes patients, study finds

A Korean study shows continuous glucose monitoring significantly reduces complications and mortality in Type 1 diabetes patients.

Daewoong’s Enavogliflozin Shows Consistent Glucose-Lowering Effects Across Korean and Chinese Patients

Daewoong's diabetes drug Enblo shows similar effects in Korean and Chinese patients, supporting its global expansion and future approvals.

Daewoong Pharmaceutical Gains Mexico Approval for Type 2 Diabetes Drug as Latin America Expansion Accelerates

Daewoong Pharmaceutical's type 2 diabetes drug Enblo has received approval in Mexico, a key market in Latin America.

Unlocking the Future of Health: How Myokines Could Revolutionize Diabetes Management in 2026

HLB Life Care signs MOU to research myokines, aiming for innovations in health and functional foods with a focus on diabetes and aging.

JW Pharmaceuticals Secures Exclusive Rights for Innovative GLP-1 Drug Vopaglutide in South Korea

JW Pharmaceutical secures exclusive rights for Vopaglutide, a promising treatment for diabetes and obesity, with significant milestone payments.

Sam Chun Dang Pharm Signs 100 Million USD Licensing Deal for Oral Generics of Rybelsus and Wegovy

Sam Chun Dang Pharm secures a U.S. licensing deal for generic diabetes and obesity medications, valued at $100 million.

New Diabetes Treatment: Chong Kun Dang’s Dubiempol Sustained Release Tablet Approved for Type 2 Diabetes in Korea

Chong Kun Dang's type 2 diabetes treatment, Dubiempol, gains approval, offering a new option for patients with uncontrolled blood sugar.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.